Answers are grounded in this paper and cite their sources.
The growing demand for evidence-based cosmetic formulations has been accompanied by an increase in registered clinical trials of topical interventions targeting skin aging and pigmentation disorders. The aim of this study was to map interventional trials registered in ClinicalTrials.gov with start dates between 2015 and 2025 and interpret them within a literature-based mechanistic framework comprising a functional classification of actives and a conceptual ingredient–mechanism–outcome diagram. Of 1104 records, 96 trials were included. Their number increased from 22 trials started in 2015–2019 to 49 in 2023–2025 (about 22% per year), mainly in the collagen/structural aging group (52.1% of trials, although only 28 trials were classified on the basis of explicit structural terms), whereas 47.9% of the registry records did not name the active ingredient investigated. The literature-based framework grouped the actives into five functional clusters with overlapping mechanisms. Only 60% of the trials registered safety outcomes, with notable variation between age-related skin phenotypes; planned sample sizes were small (median 39 participants), and only 22% of the trials combined instrumental, investigator-assessed, and participant-reported endpoints. Important limitations persist, including heterogeneity in outcome measures, limited mechanistic validation, incomplete reporting of interventions, and a lack of long-term efficacy and safety data. This study provides a registry-level overview of research activity, not an assessment of clinical efficacy, and supports more standardized, transparent, and mechanism-based approaches in cosmetic science.
No takes yet. Share an insight, caveat, or question.
Rus et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: